Physicians' Academy for Cardiovascular Education
In a prospective study using data of a large French cohort, high consumption of sugary drinks and artificially-sweetened beverages (ASBs) increased risk of CVD.
Following the results from the ORION program, the CHMP of EMA has issued a positive opinion on inclisiran to reduce LDL-c in patients with hypercholesterolemia or mixed dyslipidemia.
Prof. Deanfield emphasizes the importance of early intervention to prevent T2DM and obesity and thereby reducing lifetime CV risk.
The DA VINCI study demonstrated that the majority of prescibed therapies for lipid-lowering in Europe is monotherapy with statins and only one-third of patients met their LDL-c goal described in the 2019 dyslipidemia guidelines. With poll.
The AHA has published a scientific statement on evidence for the cardiorenal protective effects of SGLT2i and GLP-1RAs on outcomes in patients with CKD and T2DM.
RNA therapeutics can reduce production of apo(a) in hepatocyten and thereby prevent assembly of Lp(a). This presentation provides an overview of phase 2 studies with antisense mediated Lp(a) lowering.
An analysis of the CANTOS trial showed that IL-1β inhibition with canakinumab reduced total number of serious CV events compared to placebo in patients with prior MI and subclinical inflammation.
A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials found no heterogeneity between effects of dapagliflozin and empagliflozin in HFrEF patients and a reduction in non-fatal and fatal CV outcomes and renal events with these SGLT2i.
Prof. Laufs discusses the role of triglycerides and Lp(a) in the context of residual risk.
A randomized trial showed no effect of time-restricted eating on weight loss or metabolic markers compared to a standard 3-meals-per-day-diet in individuals with overweight or obesity.
The cardiac-specific myosin activator omecamtiv mecarbil significantly reduced the risk of CV death and HF events in HFrEF patients, yet failed to reduce CV death as secondary endpoint.
RAAS inhibitors can cause hyperkalemia in HF patients leading to RAASi downtitration or discontinuation. Novel potassium binders may improve management of HF patients by continuation of RAASi.
